Renovaro (NASDAQ:RENB) Posts Earnings Results

Renovaro (NASDAQ:RENB) released its quarterly earnings data on Wednesday. The company reported ($0.02) EPS for the quarter, Zacks reports.

Renovaro Stock Up 5.6 %

Shares of RENB traded up $0.05 during trading hours on Wednesday, reaching $0.86. The stock had a trading volume of 673,546 shares, compared to its average volume of 1,048,667. Renovaro has a 52 week low of $0.40 and a 52 week high of $3.38. The firm has a 50-day moving average of $0.96 and a 200 day moving average of $0.76. The company has a market cap of $136.50 million, a P/E ratio of -0.90 and a beta of 0.63.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.